(Q42622688)

English

Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer

scientific article published on 24 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer (English)

1 reference

Europe PubMed Central

3 November 2017

radiation therapy

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

D Robert Siemens

1

1 reference

Europe PubMed Central

3 November 2017

Jeremy P W Heaton

2

1 reference

Europe PubMed Central

3 November 2017

Michael A Adams

3

1 reference

Europe PubMed Central

3 November 2017

Jun Kawakami

4

1 reference

Europe PubMed Central

3 November 2017

Charles H Graham

5

1 reference

Europe PubMed Central

3 November 2017

language of work or name

0 references

publication date

24 May 2009

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

74

1 reference

Europe PubMed Central

3 November 2017

4

1 reference

Europe PubMed Central

3 November 2017

878-883

1 reference

Europe PubMed Central

3 November 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Nitric oxide-mediated regulation of chemosensitivity in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.03.004

7 January 2021

Identifiers

10.1016/J.UROLOGY.2009.03.004

1 reference

Europe PubMed Central

3 November 2017

release_x5v5ojln6jen7d5re6cey7woru

1 reference

https://api.fatcat.wiki/v0/release/x5v5ojln6jen7d5re6cey7woru

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42622688&oldid=1963306033"